Related Experiment Videos
Challenging the standard of care in advanced melanoma: focus on pembrolizumab
Raghad M Abdul-Karim1, C Lance Cowey2,3,4
1Baylor Sammons Cancer Center.
Abstract:
The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile. Additionally, this agent is being evaluated in adjuvant and combination trial strategies that have great potential to further advance outcomes. This review focuses on the advances that pembrolizumab has made in melanoma and what studies are upcoming that could change the future of melanoma treatment yet again.
Insights
Effective immunotherapies like pembrolizumab significantly improve survival for advanced melanoma patients. Upcoming trials exploring combination strategies may further advance melanoma treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced melanoma treatment has seen significant progress with novel therapies.
- Immune checkpoint inhibitors represent a new class of immunotherapy with improved response and survival rates.
Purpose of the Study:
- To review the advances of pembrolizumab in treating advanced melanoma.
- To discuss upcoming studies and their potential impact on future melanoma treatment.
Main Methods:
- This review focuses on published data and ongoing clinical trials.
- Analysis of pembrolizumab's efficacy and tolerability in advanced melanoma.
Main Results:
- Pembrolizumab, an inhibitor of the PD-1 receptor, demonstrates improved efficacy over standard therapies.
- The agent shows an acceptable tolerability profile in patients with advanced melanoma.
Conclusions:
- Pembrolizumab has significantly advanced melanoma treatment, offering improved survival outcomes.
- Further research in adjuvant and combination therapies holds promise for future treatment paradigms.